Home
    • Plans Blog Contact
    VITASPRING BIOMEDICAL CO. LTD. logo

    VITASPRING BIOMEDICAL CO. LTD.

    VSBC
    Last price US$0.0111
    Market cap US$2.3m
    12M price change N/A
    Loading the 12-month Mave Thesis and 1-month news signal

    Industry and sector peers, plus broader research alternatives

    View comparison
    Halozyme Therapeutics IncHALO Industry peer Corcept Therapeutics IncorporatedCORT Industry peer Exelixis IncEXEL Industry peer Zoetis IncZTS Sector peer
    Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Statements Financial Ratio
    Dashboard Funda..tals Prediction Screener Map

    VITASPRING BIOMEDICAL CO. LTD. Overview

    Industry: Biotechnology

    Sector: Healthcare

    VitaSpring Biomedical Co. Ltd. focuses on the development of drugs of cell medicine. The company was formerly known as Shemn Corp. and changed its name to VitaSpring Biomedical Co. Ltd. in February 2020. VitaSpring Biomedical Co. Ltd. was incorporated in 2016 and is headquartered in Irvine, California. VitaSpring Biomedical Co. Ltd. focuses on the development of drugs of cell medicine. The company was formerly known as Shemn Corp. and changed its name to VitaSpring Biomedical Co. Ltd. in February 2020. VitaSpring Biomedical Co. Ltd. was incorporated in 2016 and is headquartered in Irvine, Californ Read More

    Mavefund brings filings, fundamentals, valuation, price history and news for VITASPRING BIOMEDICAL CO. LTD. into one research view. The sections below show what strengthens or weakens the research case.

    Score

    Reported Results

    What the company reported, with filing details kept small.

    Filed Jun 17, 2026

    Quarterly result summary

    Latest company-filed earnings material is available for source review.

    What changed

    • Review the SEC source filing for the full reported results and management commentary.

    Guidance / outlook

    No formal outlook was extracted from this filing excerpt. Open the SEC source to review full management commentary.

    SEC filing Open filing

    Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

    Other recent earnings materials
    SEC filing FORM 10-Q Jun 17, 2026 SEC filing FORM 10-K Jun 17, 2026 SEC filing FORM 10-Q Jun 17, 2026 SEC filing FORM 10-Q Jun 15, 2026 SEC filing FORM 10-K Jun 08, 2026 SEC filing FORM 10-Q May 06, 2026 SEC filing FORM 10-Q Apr 22, 2026

    Prediction-grade evidence

    Recent News

    Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.

    No qualified company news in the last 14 days

    No recent article passed both the company-relevance and source-reliability checks. Research continues to use the other available filings, fundamentals, market data, and valuation inputs.

    Earnings Per Share

    Score 2.00/5
    VITASPRING BIOMEDICAL CO. LTD. earns a low score, as its Earnings Per Share (EPS) has not shown continuous growth over the last six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    In Biotechnology industry , Halozyme Therapeutics Inc , Corcept Therapeutics Incorporated , Exelixis Inc are companies with high ratings.

    Return on Equity

    Score 3.87/5
    VITASPRING BIOMEDICAL CO. LTD. stands out with a superior score in the Return on Equity (ROE) section, surpassing the sector median value and showcasing its strong performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    VITASPRING B... VSBC US$2.3m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Net Margin

    Score 2.95/5
    VITASPRING BIOMEDICAL CO. LTD. commands a high score, propelled by its net margin consistently outpacing the sector median value and exhibiting continuous growth in recent six years; noteworthy counterparts in the sector, boasting similarly high scores, include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    VITASPRING B... VSBC US$2.3m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Share Buyback

    In Biotechnology industry , Halozyme Therapeutics Inc , Corcept Therapeutics Incorporated , Exelixis Inc are companies with high ratings.

    Leverage

    Score 1.82/5
    VITASPRING BIOMEDICAL CO. LTD. registers a lower score in the category as a result of its elevated leverage ratio over the past six years compared to the sector median value. Conversely, other companies in the same sector, including Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc have achieved high scores.
    VITASPRING B... VSBC US$2.3m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Financial Statements

    Company-reported SEC EDGAR facts organized into the three core statements.

    Verified SEC statements load when this section enters view.

    Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

    Financial Ratio

    Yearly Quarterly

    Financial
    Profitability
    Growth
    Cash Flow
    Financial Health
    Efficiency Ratios

    VITASPRING BIOMEDICAL CO. LTD. logo

    VITASPRING BIOMEDICAL CO. LTD.

    US$0.0111

    US$2.3m

    0.00%

    N/A